Is Baby Aspirin Good for High Blood Pressure?

Baby aspirin does not lower blood pressure in any clinically meaningful way and is not recommended as a treatment for hypertension. Its primary job is preventing blood clots, not relaxing blood vessels or reducing the force of blood against artery walls. Some research has explored whether the timing of a low-dose aspirin can nudge blood pressure down slightly, and there are specific situations where aspirin matters for people who also have high blood pressure, but the relationship is more complicated than many people assume.

Why Aspirin Is Not a Blood Pressure Medication

Aspirin works by irreversibly blocking an enzyme called cyclooxygenase-1 (COX-1) in platelets, which reduces the production of thromboxane A2, a molecule that promotes clot formation and constricts blood vessels. At the low doses found in baby aspirin (typically 81 mg in the United States), this COX-1 blockade is the dominant effect. It makes platelets less sticky, which is why aspirin is used to prevent heart attacks and certain strokes caused by blood clots. The reduction in thromboxane A2 does have a minor vasodilatory consequence, but it is far too small to serve as blood pressure therapy.¹

At higher doses, aspirin also blocks COX-2, which is the enzyme responsible for producing prostacyclin, a potent vasodilator. Blocking COX-2 can actually work against blood pressure reduction by removing one of the body’s natural mechanisms for keeping vessels relaxed. This means that taking more aspirin does not help and could theoretically be counterproductive for blood pressure. The standard antihypertensive drugs, things like ACE inhibitors, calcium channel blockers, and diuretics, work through entirely different pathways and are orders of magnitude more effective at controlling blood pressure.

There is also a separate laboratory finding that aspirin can trigger the release of nitric oxide from the lining of blood vessels, which would promote relaxation. But this effect, demonstrated at the cellular level, has not translated into a reliable blood-pressure-lowering effect in clinical practice.²

The Bedtime Dosing Debate

One of the more interesting wrinkles in the aspirin-and-blood-pressure story is the question of when you take it. Several studies have found that aspirin taken at bedtime, rather than in the morning, produces a small but detectable drop in blood pressure over the following months. A 2024 meta-analysis pooling multiple trials found that bedtime dosing lowered systolic blood pressure by roughly 3.7 mmHg more than morning dosing, with very little variation between the studies.³ An older but well-known trial in hypertensive patients found a reduction of about 6.8/4.6 mmHg in systolic and diastolic blood pressure when aspirin was given before bed.⁴

The theory behind this is tied to circadian rhythms. Blood pressure naturally dips during sleep and surges in the early morning, and the body’s clotting and inflammatory systems follow their own daily cycles. Taking aspirin before bed might suppress overnight thromboxane production during a window when it has the greatest influence on vascular tone.

But the evidence is not unanimous. A randomized crossover trial specifically designed to test this question in patients with cardiovascular disease found no meaningful blood pressure difference between bedtime and morning dosing.⁵ And a systematic review comparing aspirin taken on waking versus with other timing found that morning aspirin had essentially no effect on blood pressure at all, while bedtime aspirin showed a modest reduction in systolic pressure but a less convincing effect on diastolic pressure.⁶

Even in the studies where bedtime aspirin did lower blood pressure, the effect was modest. A drop of 3 to 7 mmHg is meaningful in the context of population-level cardiovascular risk, but it is nowhere near what a proper antihypertensive medication delivers. No guidelines recommend aspirin as a substitute for blood pressure drugs, and no doctor would prescribe it for that purpose alone.

What Aspirin Actually Does for People With High Blood Pressure

The reason aspirin has historically been part of the conversation around hypertension is not that it lowers blood pressure. It is that high blood pressure raises the risk of heart attacks and strokes, and aspirin can reduce the likelihood of some of those events. The landmark Hypertension Optimal Treatment (HOT) trial, which enrolled nearly 19,000 hypertensive patients, found that low-dose aspirin cut major cardiovascular events by 15% and heart attacks specifically by 36%.⁷ Aspirin had no effect on stroke in that trial, which makes sense: it prevents clot-based (ischemic) strokes but does nothing against strokes caused by bleeding, which are more tightly linked to high blood pressure.

One concern people reasonably have is whether adding aspirin on top of blood pressure medications could interfere with those drugs. The answer, at least for low-dose aspirin, appears to be no. A study looking at long-term use found that low-dose aspirin did not blunt the blood-pressure-lowering effects of antihypertensive agents, including ACE inhibitors.⁸ In a small trial of patients who had both high blood pressure and high cholesterol and were already on statins and antihypertensives, adding low-dose aspirin actually improved blood vessel function and coincided with modest blood pressure reductions of about 5 to 6 mmHg systolic.⁹ That finding is worth noting but should be taken in context: these were patients on multiple medications already, and the blood vessel improvements may have been doing the heavy lifting.

The Bleeding Trade-Off

Every conversation about aspirin has to account for its most significant downside: bleeding. By making platelets less able to form clots, aspirin makes it easier to bleed, particularly in the stomach and intestines. Across large pooled analyses, low-dose aspirin increased the risk of major gastrointestinal bleeding by about 58% and raised the risk of bleeding inside the skull by roughly 30 to 40%.¹⁰¹¹ In absolute terms, the extra risk of a major gut bleed works out to roughly 1 to 2 additional events per 1,000 people per year of aspirin use. That sounds small, but it compounds over time and becomes less favorable as people age.

For people with uncontrolled high blood pressure specifically, the bleeding risk is amplified. Elevated blood pressure is itself a risk factor for hemorrhagic stroke, and adding aspirin into that picture can be dangerous. A study of elderly patients with multiple cardiovascular risk factors found that aspirin was associated with a more than threefold increase in hemorrhagic stroke among those in the highest blood pressure group.¹² This is a critical point: aspirin is riskier when blood pressure is poorly controlled. Getting blood pressure under control first is essential before aspirin can offer a favorable benefit-to-harm ratio.

Analysis of nearly 200,000 patients across 31 trials confirmed that lower aspirin doses carry the lowest bleeding risk, and that doses above 100 mg per day escalate bleeding, particularly gastrointestinal and total bleeding events.¹³ If aspirin is going to be used, keeping the dose low matters.

Why Guidelines Have Narrowed

For decades, a daily baby aspirin was considered almost routine for middle-aged and older adults worried about their hearts. That era is largely over. Several major trials published in the late 2010s showed that for people without established heart disease, the benefits of aspirin were marginal while the bleeding risks were real. The most influential of these was the ASPREE trial, which enrolled over 19,000 healthy adults aged 70 and older. After nearly five years, aspirin provided no benefit for disability-free survival compared to placebo. The rate of death, dementia, or persistent disability was virtually identical in both groups. Meanwhile, major hemorrhage was significantly more common in the aspirin group.¹⁴

The U.S. Preventive Services Task Force now recommends against starting aspirin for cardiovascular prevention in adults 60 and older, and says the decision for adults aged 40 to 59 with elevated cardiovascular risk should be individualized, with the understanding that the net benefit is small. Pooled data from 11 trials showed aspirin reduced nonfatal heart attacks and ischemic strokes by about 12% each, but increased major gastrointestinal bleeding by 58% and intracranial bleeds by 31%.¹⁵

A benefit-harm modeling study tried to estimate who actually comes out ahead from aspirin for primary prevention. The results were striking: only about 2.5% of women and 12% of men were likely to have a net benefit if you weigh one prevented cardiovascular event as equal in severity to one major bleed. Those percentages grew if you assumed cardiovascular events are twice as bad as bleeds, but even then, the majority of people did not clearly benefit.¹⁶

This shift has created a practical challenge. Millions of people started taking daily aspirin years ago based on older guidelines and never stopped. Guidance on how to safely stop aspirin in people who have been taking it for primary prevention is still surprisingly sparse.¹⁷ If you are in this group, the right move is to talk to your doctor rather than stopping abruptly on your own.

Aspirin and Kidney Disease in Hypertensive Patients

One population where the calculus looks different is people with both high blood pressure and chronic kidney disease. Reduced kidney function is itself a major cardiovascular risk factor, and the HOT trial’s post-hoc analysis found that as kidney function declined, the benefit of aspirin grew sharply. Among hypertensive patients with severely reduced kidney function, aspirin cut major cardiovascular events by about two-thirds and total mortality by nearly half.¹⁸ A 2024 meta-analysis confirmed this pattern, finding that aspirin significantly reduced cardiovascular death and overall mortality in patients with moderate to severe kidney disease, though the risk of major bleeding was also elevated by about 50%.¹⁹

For this specific group, the absolute benefit can substantially outweigh the bleeding risk. The HOT trial estimated that for every 1,000 patients with severely reduced kidney function treated with aspirin for about four years, 76 major cardiovascular events and 54 deaths would be prevented, at the cost of 27 extra major bleeds.¹⁸ That is a trade-off most people and their doctors would accept.

Aspirin in Pregnancy and Preeclampsia Prevention

Preeclampsia is a dangerous pregnancy complication characterized by a sudden rise in blood pressure, and low-dose aspirin has become a standard recommendation for women at high risk. The American College of Obstetricians and Gynecologists recommends starting low-dose aspirin between 12 and 28 weeks of gestation for women with risk factors. The logic is partly about blood pressure, but more about the underlying placental dysfunction that drives preeclampsia.

The evidence here is real but more nuanced than the recommendation alone suggests. A systematic review across diverse populations found that aspirin significantly reduced preeclampsia in some groups but not others. Among non-Hispanic white women in one trial, the reduction was significant, but Hispanic and Black women did not see the same benefit. In women already classified as high risk, aspirin did not significantly reduce preeclampsia incidence in several studies.²⁰

As with the general hypertension research, timing matters. A study of pregnant women found that the blood-pressure-lowering effect of aspirin was strongly time-dependent, with aspirin given later in pregnancy and at bedtime showing the largest reductions compared to placebo, reaching about 12 mmHg systolic and 8 mmHg diastolic by delivery.²¹ A review of the evidence for women with chronic hypertension specifically found that higher doses of at least 150 mg, started before 12 weeks and taken at bedtime, showed the most promising trend, though the overall effectiveness against superimposed preeclampsia was limited because aspirin targets only one of several disease pathways.²²

Aspirin Resistance and Self-Medication

Not everyone who takes aspirin gets the expected antiplatelet effect. Aspirin resistance, where the drug fails to adequately suppress platelet activity, affects a substantial minority of patients. In one study of hypertensive patients, about 20% showed laboratory evidence of aspirin resistance. The strongest predictors were female sex, higher creatinine levels, and lower platelet counts.²³ For these individuals, the already modest cardiovascular protection aspirin provides may be even smaller than expected.

Meanwhile, self-medication with aspirin remains common. A study on cardiovascular self-medication found that 65% of participants were treating cardiovascular conditions on their own, with aspirin being one of the most frequently used drugs. Many were taking it for suspected cardiovascular risk without any medical guidance, exposing themselves to bleeding risks without knowing whether the trade-off was worthwhile for their individual situation.²⁴

The accessibility of baby aspirin, its inexpensive price, and decades of marketing as a heart-health staple have created a situation where many people take it reflexively. If you have high blood pressure and are thinking about adding aspirin to your routine, the most important step is not buying the aspirin. It is getting your blood pressure properly controlled with proven antihypertensive medications first, then having a conversation with a doctor about whether your personal cardiovascular risk and bleeding risk profile make aspirin worthwhile. For most people without established heart disease, the answer is increasingly that it is not.